CELL INCORPORATION STUDY OF [99mTc]Tc-NAB-PACLITAXEL ON HUMAN COLORECTAL ADENOCARCINOMA CELL LINE

Abstract

Objective: The development of new radiopharmaceuticals capable of specifically imaging cancer is an important research area. For this reason, the aim of this study is to investigate cell binding of novel developed nanoradiopharmaceutical ([99mTc]Tc-nab-PTX) on HT-29 cell line (human colorectal adenocarcinoma cells). Material and Method: In this study, nab-PTX was labeled with [99mTc]Tc, and labeling efficiency and in vitro stability were investigated by radioactive thin layer chromatography (RTLC). Then, cell incorporation of [99mTc]Tc-nab-PTX was performed using HT-29 cell line. Result and Discussion: According to obtained results, nab-PTX was labeled with high radiochemical purity (>99%). The [99mTc]Tc-nab-PTX was found to be stable in saline for 6-h, and in cell medium up to 2-h. It was determined that [99mTc]Tc-nab-PTX had a greater cell binding activity on HT-29 cells than R/H-[99mTc]NaTcO4 at 30 min. The results were found to be promising for future in vivo studies with [99mTc]Tc-nab-PTX.